Home:
Educational
Supplement: Section 1
OVERVIEW
OF COOPERATIVE CLINICAL RESEARCH GROUPS
Through the
Cooperative Group Program, the National Cancer Institute supports
groups of researchers, cancer centers and community physicians across
the country and in Canada and Europe. These groups conduct large,
phase III clinical trials as well as smaller phase I and II clinical
trials, cancer control and prevention trials. Each Cooperative Group
within the NCI program is supported to continually generate new
trials compatible with its particular areas of interest and expertise,
as well as with national priorities for cancer treatment research.
The development of large, multicenter trials for investigational
agents allows the rapid accrual of patients while reducing the possible
bias of studies carried out at a single or a few institutions.
The NCI currently
lists 11 adult cancer cooperative groups, nine of which conduct
breast cancer treatment trials. All the cooperative group trials
are listed in NCI's clinical trials database at http://cancernet.nci.nih.gov/trialsrch.shtml,
which can be searched by research groups or specific trials. The
Cancer Information Service (1-800-4-CANCER) also provides contact
and eligibility information for all cooperative group clinical trials.
LIST
OF ADULT CANCER COOPERATIVE GROUPS AND BREAST CANCER CLINICAL TRIALS
Web
link
(Note: Many of
these studies are discussed further in this book and the poster exhibit.)
AMERICAN
COLLEGE OF RADIOLOGY IMAGING NETWORK (ACRIN) Web
link
The primary
goal of the American College of Radiology Imaging Network (ACRIN)
is to generate information through clinical trials of diagnostic
imaging and image-guided therapeutic technologies that will lengthen
and improve the quality of the lives of cancer patients. ACRIN is
currently funded by the NCI for five years (1999 - 2004). Unlike
other cooperative groups, ACRIN has no permanent members. Rather,
institutions become qualified to participate in trials conducted
by ACRIN's Institutional Participants Committee.
Open Breast
Cancer Protocols
ACRIN-6652
Screening and Diagnostic Study of Digital Mammography Versus
Screen-Film Mammography in the Detection of Breast Cancer in
Women Protocol
CONTACT INFORMATION
ACRIN Network Chair: Dr Bruce Hillman
Phone: (804) 982-0211, E-mail: bjh8a@virginia.edu
ACRIN Administrator:
Irene Mahon
Phone: (215) 574-3231, E-mail: IMAHON@phila.acr.org
AMERICAN
COLLEGE OF SURGEONS ONCOLOGY GROUP (ACOSOG) Web
link
The American
College of Surgeons Oncology Group (ACSOG) is a multidisciplinary
cooperative group that focuses on evaluating diagnostic and therapeutic
procedures in patients with the most common malignant solid tumors
including breast, lung and colorectal cancers. Membership includes
general and specialty surgeons, medical oncologists, gynecologists,
radiologists, radiation therapists, geneticists, basic laboratory
investigators and allied health professionals in the private community
as well as at academic centers.
Open Breast
Cancer Protocols
ACOSOG-Z0010;
GUMC-00152
Phase III Prognostic Study of Sentinel Node and Bone Marrow
Micrometastases in Women with Stage I or IIA Breast Cancer
Protocol
ACOSOG-Z0011;
GUMC-00153
Phase III Randomized Study of Axillary Lymph Node Dissection
in Women with Stage I or IIA Breast Cancer Who Have a
Positive Sentinel Node Protocol
CONTACT INFORMATION
American College of Surgeons Oncology Group
Box 3627
Duke University Medical Center
Durham, NC 27710
Phone: (919) 668-8549, Fax: (919) 668-7122
Group Chair:
Samuel A Wells, Jr, MD, FACS
Phone: (919) 668-8435, E-mail: wells029@surgerytrials.duke.edu
Group Administrator:
Mary Ruemker
Phone: (919) 668-8018, E-mail: ruemk001@surgerytrials.duke.edu
CANCER
AND LEUKEMIA GROUP B (CALGB) Web
link
The Cancer and
Leukemia Group B (CALGB) is a national clinical research group that
conducts clinical trials in patients with leukemia, lymphoma, melanoma,
breast cancer, lung cancer, genitourinary malignancies, gastrointestinal
malignancies and prostate cancer. CALGB's studies aim to reduce
the morbidity and mortality from cancer, relate the biological characteristics
of cancer to clinical outcomes and develop new strategies for the
early detection and prevention of cancer. CALGB is headquartered
at the University of Chicago, and its statistical center is located
at Duke University. Founded in 1955, CALGB has grown into a network
of 29 university medical centers, over 185 community hospitals and
more than 3,000 physicians.
Open Breast
Cancer Protocols
CLB-9871
Phase II Study of Docetaxel in Caucasian and African American Patients
with Solid Tumors Protocol
CLB-49808; CTSU
Phase III Randomized Study of Doxorubicin and Cyclophosphamide with
or without Dexrazoxane, Followed by Paclitaxel with or without Trastuzumab
(Herceptin), Followed by Surgery and Radiotherapy with or without
Trastuzumab in Women with HER2+ Stage IIIA or IIIB or Regional Stage
IV Breast Cancer Protocol
CAN-NCIC-MA17;
CLB-49805; EORTC-10983; JRF-Vor-Int-10; NCCTG-CAN-MA17; SWOG-CAN-MA17
Phase III Randomized Study of Letrozole Versus Placebo in Women
with Primary Breast Cancer Who Have Completed at Least Five Years
of Adjuvant Tamoxifen Protocol
CLB-9840; CTSU
Phase III Randomized Study of Paclitaxel Via One Hour Infusion Every
Week Versus Three Hour Infusion Every 3 Weeks with or without Trastuzumab
(Herceptin) in Patients with Inoperable, Recurrent or Metastatic
Breast Cancer with or without Overexpression of HER2-Neu Protocol
CLB-79809; NCI-P01-0184
Phase III Randomized Study of Zoledronate, Calcium and Cholecalciferol
(Vitamin D) to Prevent Bone Loss in Women with Breast Cancer Receiving
Adjuvant Chemotherapy Protocol
CONTACT INFORMATION
CALGB Central Office
208 South LaSalle Street, Suite 2000
Chicago, IL 60604
Phone: (773) 702-9171, Fax: (312) 345-0117
EASTERN
COOPERATIVE ONCOLOGY GROUP (ECOG) Web
link
The Eastern
Cooperative Oncology Group (ECOG) is a large network of researchers,
physicians and healthcare professionals at public and private institutions
working toward the common goal of controlling, effectively treating
and ultimately curing cancer. Established in 1955 as one of the
first cooperative groups, ECOG has evolved into one of the largest
clinical cancer research organizations in the U.S. with almost 6,000
physicians, nurses, pharmacists, statisticians and clinical research
associates (CRAs) from the U.S., Canada and South Africa. Currently,
ECOG has more than 90 active clinical trials in all types of adult
malignancies. The group's annual accrual is 6,000 patients, with
more than 20,000 patients in follow-up.
Open Breast
Cancer Protocols
E-3198
Phase II Study of Doxorubicin HCl Liposome and Docetaxel with or
without Trastuzumab (Herceptin) in Women with Metastatic Breast
Cancer Protocol
E-1199
Phase III Study of Doxorubicin and Cyclophosphamide Followed by
Paclitaxel or Docetaxel in Women with Node-Positive or High-Risk
Node-Negative Stage II or IIIA Breast Cancer Protocol
E-1Y97
Genetic Mapping of Interactive Susceptibility Loci in Patients and
Siblings with Breast, Colon, Lung or Prostate Cancer Protocol
E-3Z93; NCI-P95-0068
Randomized Pilot Study to Evaluate Educational Intervention and
Behavioral Skills Training for Pain Control in Patients with Recurrent
or Metastatic Breast or Prostate Cancer Protocol
E-1Y92; NCI-P93-0042
Randomized Study of Brief Physician-Initiated Smoking Cessation
Strategies Versus Usual Care in Patients with Early Stage Cancer
Who Are Undergoing Treatment in Clinical Oncology Settings Protocol
E-5194
Screening Study Following Local Excision in Selected Patients with
Ductal Carcinoma in Situ (DCIS) of the Breast Protocol
CONTACT INFORMATION
ECOG Group Chair's Office
1818 Market Street, Suite 1100
Philadelphia, PA 19103
Phone: (215) 789-3645, Fax: (267) 256-5291
ECOG Coordinating
Center
Frontier Science
303 Boylston Street
Brookline, MA 02445-7648
Phone: (617) 632-3610, Fax: (617) 632-2990
EUROPEAN
ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER (EORTC) Web
link
The European
Organization for Research and Treatment of Cancer (EORTC) aims to
conduct, develop, coordinate and stimulate laboratory and clinical
research to improve the management of cancer and related problems
by increasing patients' survival and quality of life. EORTC consists
of a network of scientists and clinical oncologists working in the
main cancer research institutes of the European Union countries.
The organization conducts multicenter clinical trials throughout
Europe as well as intergroup studies in Australia, USA and Canada.
First established as an international organization under Belgian
law in 1962, the organizations became the "European Organisation
for Research and Treatment of Cancer" (EORTC) in 1968. Core
support for the EORTC Data Center has been provided by the NCI since
1972. Over 40 countries participate in EORTC clinical trials with
an accrual of 6,509 new patients in the year 2000.
Open Breast
Cancer Protocols
EORTC-16001
Phase II Study of Oxaliplatin in Women with Advanced or Metastatic
Breast Cancer Following Failure of Anthracycline/Taxane-Based Chemotherapy
Protocol
EORTC-10951;
PHARMACIA-EORTC-10951
Phase II/III Randomized Study of First-Line Hormonal Therapy with
Exemestane Versus Tamoxifen in Postmenopausal Women with Locally
Recurrent or Metastatic Breast Cancer Protocol
EORTC-10963
Phase III Randomized Neoadjuvant Study of ICI 182780 in Women with
Stage I or II Primary Breast Cancer Protocol
EORTC-19951
Phase III Randomized Study of Amphotericin B-Liposomal Formulation
Initiated 72-84 Hours vs 144-156 Hours After Onset of a Febrile
Episode in Cancer Patients with Granulocytopenia and Persistent
Unexplained Fever Refractory to Antibacterials Protocol
EORTC-10981;
EORTC-10981-AMAROS
Phase III Randomized Study of Complete Axillary Lymph Node Dissection
Versus Axillary Radiotherapy in Sentinel Lymph Node-Positive Women
with Operable Invasive Breast Cancer Protocol
EORTC-10925
Phase III Randomized Study of Internal Mammary and Medial Supraclavicular
Lymph Node Chain Irradiation vs No Further Therapy in Women with
Resected Stage I/II/III Breast Cancer Protocol
CAN-NCIC-MA17;
CLB-49805; EORTC-10983; JRF-Vor-Int-10; NCCTG-CAN-MA17; SWOG-CAN-MA17
Phase III Randomized Study of Letrozole Versus Placebo in Women
with Primary Breast Cancer Who Have Completed at Least Five Years
of Adjuvant Tamoxifen Protocol
EORTC-10994
Phase III Randomized Study of Neoadjuvant Fluorouracil, Epirubicin
and Cyclophosphamide Versus Neoadjuvant Docetaxel and Epirubicin
Followed by Radiotherapy and Surgery in Women with Locally Advanced,
Inflammatory or Large Operable Breast Cancer Protocol
EORTC-05971
Randomized Study of Vinorelbine Combined with Chronomodulated Fluorouracil
in Previously Treated Women with Metastatic Breast Cancer
Protocol
CONTACT INFORMATION
EORTC Central Office
Av. E. Mounier 83 Box 11
1200 Brussels, Belgium
Director General: Françoise Meunier
E-mail: fme@eortc.be
Assistant to the Director General: Tina Delparte
Phone: +32 2 774 16 41, E-mail: tde@eortc.be
GYNECOLOGIC
ONCOLOGY GROUP (GOG) Web
link
The Gynecologic
Oncology Group (GOG) is a national organization dedicated to clinical
research in the field of gynecologic cancers including cancers that
arise from the ovaries, uterus, cervix, vagina and vulva. Its aim
is to improve the treatment of gynecologic cancer through research
encompassing sur-gery, radiation therapy, chemotherapy, pathology,
immunology and/or gynecologic nursing. GOG consists of over 60 "parent"
institutions, medical schools, colleges and universities and more
than 125 affiliated hospitals. There are approximately 45 clinical
trials active at any given time.
CONTACT INFORMATION
GOG Statistical and Data Center
Roswell Park Cancer Institute
Elm & Carlton Streets
Buffalo, NY 14263-0001
Phone: (716) 845-5702
GOG Administrative Office
1234 Market Street, Suite 1945
Philadelphia, PA 19107
Phone: (215) 854-0770
NATIONAL
CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP (NCIC) Web
link
The National
Cancer Institute of Canada Clinical Trials Group (NCIC CTG) is a
cooperative group that conducts clinical trials in cancer therapy
and supportive care throughout Canada and internationally. The organization
aims to undertake and support research that will lead to reduction
in the incidence of and morbidity and mortality from cancer. NCIC
established the clinical trials program in 1971 in response to investigators
interested in carrying out multicenter trials in Hodgkin's disease
and hypernephroma. The Investigational New Drug (IND) program was
established in 1982 and now conducts phase I and II trials with
cytotoxics and biologics. New agents from the NCI (US) as well as
the pharmaceutical industry are studied.
Open Breast
Cancer Protocols
CAN-NCIC-MA20
Phase III Randomized Study of Adjuvant Breast Radiotherapy with
or without Regional Radiotherapy in Women with Resected, Early Stage,
Invasive Breast Cancer Protocol
CAN-NCIC-MA21;
AMGEN-CAN-NCIC-MA21; BMS-CAN-NCIC- MA21; JANSSEN-CAN-NCIC-MA21;
P-UPJOHN-CAN-NCIC-MA21
Phase III Randomized Study of Adjuvant Cyclophosphamide, Epirubicin
and Fluorouracil Versus Cyclophosphamide, Epirubicin, Filgrastim
(G-CSF) and Epoetin Alfa Followed by Paclitaxel Versus Cyclophosphamide
and Doxorubicin Followed by Paclitaxel in Premenopausal or Early
Postmenopausal Women with Previously Resected Node-Positive or High-Risk
Node-Negative Stage I-IIIA Breast Cancer Protocol
CAN-NCIC-MA17;
CLB-49805; EORTC-10983; JRF-Vor-Int-10; NCCTG-CAN-MA17; SWOG-CAN-MA17
Phase III Randomized Study of Letrozole Versus Placebo in Women
with Primary Breast Cancer Who Have Completed at Least Five Years
of Adjuvant Tamoxifen Protocol
CONTACT INFORMATION
Central Office Staff
Queens University
82-84 Barrie Street
Kingston, Ontario
Phone: (613) 533-6430
Dr. Joseph L. Pater, Group Director
E-mail: jpater@ctg.queensu.ca
NORTH
CENTRAL CANCER TREATMENT GROUP (NCCTG) Web
link
The North Central
Cancer Treatment Group (NCCTG) conducts clinical trials in the treatment
of a wide variety of cancers, as well as studies in the control
and prevention of cancer. NCCTG is comprised of approximately 20
community clinics consisting of over 700 physicians and 375 allied-health
professionals. Based at the Mayo Cancer Center in Rochester, MN,
NCCTG affiliates are located in 11 states and one Canadian province.
Open Breast
Cancer Protocols
NCCTG-963255
Phase II Randomized Study of Irinotecan for Refractory Metastatic
Breast Cancer Protocol
NCCTG-983252
Phase II Randomized Study of Paclitaxel, Carboplatin and Trastuzumab
(Herceptin) as First-Line Chemotherapy in Women with Overexpressed
HER-2, Metastatic Breast Cancer Protocol
NCCTG-N9932
Phase II Study of Docetaxel and Carboplatin as First-Line Therapy
in Patients with Metastatic Adenocarcinoma of the Breast Protocol
NCCTG-N0032
Phase II Study of Fulvestrant (ICI 182780) in Women with Metastatic
Breast Cancer Who Have Failed Aromatase Inhibitor Therapy Protocol
NCCTG-N003A
Phase II Study of Oral Vinorelbine in Elderly Women with Stage IV
Breast Cancer Protocol
NCCTG-N0031
Phase II Study of Topical Ceramide Cream in Women with Cutaneous
Breast Cancer Protocol
NCCTG-N9831;
GUMC-00224
Phase III Randomized Study of Doxorubicin Plus Cyclophosphamide
Followed by Paclitaxel with or without Trastuzumab (Herceptin) in
Patients with HER-2 Overexpressing Breast Cancer Protocol
NCCTG-979253;
NCI-P98-0133
Phase III Randomized Study of Epoetin Alfa in Anemic Patients with
Advanced Cancer Undergoing Chemotherapy Protocol
CAN-NCIC-MA17;
CLB-49805; EORTC-10983; JRF-Vor-Int-10; NCCTG-CAN-MA17; SWOG-CAN-MA17
Phase III Randomized Study of Letrozole Versus Placebo in Women
with Primary Breast Cancer Who Have Completed at Least Five Years
of Adjuvant Tamoxifen Protocol
NCCTG-N9431
Correlation of Menstrual Cycle Phase at the Time of Surgery with
Disease-Free Survival in Women with Stage I/II Breast Cancer Protocol
CONTACT INFORMATION
NCCTG Operations Office
Plummer Building
200 1st Street, SW
Rochester, MN 55905
Fax: (507) 284-1902
E-mail: ncctg@mayo.edu
NATIONAL
SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP) Web
link
The National
Surgical Adjuvant Breast and Bowel Project (NSABP) conducts clinical
trials in breast and colorectal cancer at hundreds of locations
around the country. In addition to treatment trials, NSABP conducts
large prevention trials including the STAR trial (Study of Tamoxifen
and Raloxifene) Established over 40 years ago, NSABP now conducts
research at nearly 200 medical centers, university hospitals, large
oncology practice groups and health maintenance organizations in
the United States, Canada, Puerto Rico and Australia. Those sites
and their satellites include more than 5,000 physicians, nurses
and other medical professionals who have enrolled more than 60,000
women and men in clinical trials in breast and colorectal cancer
since the inception of the organization.
Open Breast
Cancer Protocols
NSABP-B-34;
CTSU
Phase III Randomized Study of Adjuvant Clodronate with or without
Systemic Chemotherapy and/or Tamoxifen in Women with Early-Stage
Breast Cancer Protocol
NSABP-B-30;
CTSU
Phase III Randomized Study of Adjuvant Doxorubicin and Cyclophosphamide
Followed by Docetaxel Versus Doxorubicin and Docetaxel Versus Doxorubicin,
Docetaxel and Cyclophosphamide in Women with Breast Cancer and Positive
Axillary Nodes Protocol
NSABP-B-31
Phase III Randomized Study of Doxorubicin and Cyclophosphamide Followed
by Paclitaxel with or without Trastuzumab (Herceptin) in Women with
Node-Positive Breast Cancer That Overexpresses HER2 Protocol
NSABP-B-33;
CTSU
Phase III Randomized Study of Exemestane in Postmenopausal Women
with Resected Stage I, II or IIIA Breast Cancer Who Have Completed
Five Years of Tamoxifen Protocol
NSABP-B-32
Phase III Randomized Study of Sentinel Node Dissection with or without
Conventional Axillary Dissection in Women with Clinically Node-Negative
Breast Cancer Protocol
NSABP-P-2
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast
Cancer Protocol
CONTACT INFORMATION
Operations Center
East Commons Professional Building
Four Allegheny Center - 5th Floor
Pittsburgh, PA 15212-5234
Phone: (412) 330-4600, Fax: (412) 330-4660
Biostatistical Center
One Sterling Plaza
201 North Craig Street, Suite 500
Pittsburgh, PA 15213
Phone: (412) 624-2666, Fax: (412) 624-1082
RADIATION
THERAPY ONCOLOGY GROUP (RTOG) Web
link
The Radiation
Therapy Oncology Group (RTOG) conducts clinical trials employing
radiotherapy alone and in combination with other modalities (such
as surgery and/or chemotherapy) as well as different radiotherapeutic
modalities such as implantation (brachytherapy), radiosurgery and
three dimensional conformal treatment planning. Headquartered in
Philadelphia, RTOG is comprised of 250 major research institutions
nationally and in Canada. With almost 30 years of experience, RTOG
currently has 40+ active studies.
Open Breast
Cancer Protocols
RTOG-9714; NCI-P97-0124
Phase III Randomized Study of Palliative Radiation Therapy for Bone
Metastases from Breast or Prostate Cancer Protocol
RTOG-9804; CTSU;
RTOG-DEV-1026
Phase III Randomized Study of Tamoxifen with or without Radiotherapy
in Women with Ductal Carcinoma In Situ (DCIS) of the Breast Protocol
CONTACT INFORMATION
RTOG
1101 Market Street, 14th Floor
Philadelphia, PA 19107
Phone: (215) 574-3205
Fax: (215) 928-0153
Tim McKeough, RTOG Group Administrator
E-mail: tmckeough@phila.acr.org
SOUTHWEST
ONCOLOGY GROUP (SWOG) Web
link
The Southwest
Oncology Group (SWOG) conducts clinical trials and basic research
in the prevention and cure of cancer in adults. Headquartered in
Texas, the group consists of almost 4,000 physicians at 283 institutions
throughout the United States and Canada. Since its inception in
1956, SWOG has enrolled more than 150,000 in clinical trials.
Open Breast
Cancer Protocols
SWOG-S0102
Phase II Study of Docetaxel, Vinorelbine and Filgrastim (G-CSF)
in Women with HER-2 Negative Stage IV Breast Cancer Protocol
CAN-NCIC-MA17;
CLB-49805; EORTC-10983; JRF-Vor-Int-10; NCCTG-CAN-MA17; SWOG-CAN-MA17
Phase III Randomized Study of Letrozole Versus Placebo in Women
with Primary Breast Cancer Who Have Completed at Least Five Years
of Adjuvant Tamoxifen Protocol
SWOG-S9630;
SWOG-9630
Phase III Randomized Study of Medroxyprogesterone Acetate and Observation
for Prevention of Endometrial Pathology in Patients with Postmenopausal
Breast Cancer Treated with Adjuvant Tamoxifen Protocol
SWOG-S0012;
CTSU
Phase III Randomized Study of Neoadjuvant Doxorubicin and Cyclophosphamide
with or without Filgrastim (G-CSF) in Women with Inflammatory or
Estrogen Receptor-Negative Locally Advanced Breast Cancer Protocol
SWOG-S9927;
GUMC-00223
Phase III Randomized Study of Postmastectomy Radiotherapy in Women
with Stage II Breast Cancer with One to Three Positive Nodes Protocol
SWOG-S9905
Phase III Randomized Study of Zoledronate as Adjuvant Therapy in
Patients with Stage I, II or IIIA Nonmetastatic Breast Cancer Protocol
SWOG-9342
Companion Study to Evaluate Late Cardiac Effects in Women with Node-Negative
Breast Cancer Receiving Adjuvant Chemotherapy on Protocol SWOG-8897
Protocol
CONTACT INFORMATION
SWOG
14980 Omicron Drive
San Antonio, TX 78245-3217
Phone: (210) 677-8808, Fax: (210) 677-0006
Page
4 of 4
Back | Select Publications
Top
Additional
Sections:
1 | 2
| 3 | 4
| 5 | 6
| 7 | 8
| 9 | 10
| 11 | 12
|
|